Literature DB >> 24492366

Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients.

Elodie Valade1, Jean-Marc Tréluyer, Naïm Bouazza, Jade Ghosn, Frantz Foissac, Sihem Benaboud, Floris Fauchet, Jean-Paul Viard, Saïk Urien, Déborah Hirt.   

Abstract

The aims of this study were to describe emtricitabine concentration-time courses in a large population of HIV-1-infected adults, to evaluate the influence of renal function on emtricitabine disposition, and to assess current dosing adjustment recommendations. Emtricitabine blood plasma concentrations were determined from samples collected from 161 adult patients during therapeutic drug monitoring and measured by liquid chromatography coupled to tandem mass spectrometry. The data were analyzed by a population approach. Emtricitabine pharmacokinetics was best described by a two-compartment model in which the absorption and distribution rate constants were assumed to be equal. Typical population parameter estimates (interindividual variability) were apparent elimination and intercompartmental clearances of 15.1 liters/h (17.4%) and 5.75 liters/h, respectively, and apparent central and peripheral volumes of distribution of 42.3 liters and 55.4 liters, respectively. The apparent elimination clearance was significantly related to creatinine clearance (CLCR), reflecting renal function. For 200 mg once a day (QD), the median area under the concentration-time curve over 24 h (AUC0-24) was 12.5 mg·h/liter for patients with normal renal function (CLCR, >80 ml/min), 14.7 mg·h/liter for patients with mild renal impairment (CLCR, 79 to 50 ml/min), and 17.9 mg·h/liter for patients with moderate renal impairment (CLCR, 49 to 30 ml/min). Simulations of the recommended dosing schemes for the oral solid form of emtricitabine (i.e., 200 mg per 48 h according to renal function) led to lower emtricitabine exposures for patients with moderate renal impairment (median AUC0-48, 17.2 mg·h/liter) than for patients with normal renal function (median AUC0-48, 25.6 mg·h/liter). Administering 18 ml of emtricitabine oral solution (10 mg/ml) QD to patients with moderate renal impairment should yield emtricitabine exposures similar to those in patients with normal renal function.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24492366      PMCID: PMC4023733          DOI: 10.1128/AAC.02058-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software.

Authors:  Marc Lavielle; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-01-09       Impact factor: 2.745

3.  Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.

Authors:  Vincent Jullien; Jean-Marc Tréluyer; Elisabeth Rey; Patrick Jaffray; Anne Krivine; Laurence Moachon; Agnès Lillo-Le Louet; Anne Lescoat; Nicolas Dupin; Dominique Salmon; Gérard Pons; Saïk Urien
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Pharmacokinetic model equations for the one- and two-compartment models with first-order processes in which the absorption and exponential elimination or distribution rate constants are equal.

Authors:  H P Wijnand
Journal:  J Pharmacokinet Biopharm       Date:  1988-02

Review 5.  Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.

Authors:  Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

6.  Very high concentrations of active intracellular phosphorylated emtricitabine in neonates (ANRS 12109 trial, step 2).

Authors:  Déborah Hirt; Alain Pruvost; Didier K Ekouévi; Saïk Urien; Elise Arrivé; Mamourou Kone; Eric Nerrienet; Mandisa Nyati; Glenda Gray; Leang Sim Kruy; Stéphane Blanche; François Dabis; Jean-Marc Tréluyer
Journal:  Antimicrob Agents Chemother       Date:  2011-04-04       Impact factor: 5.191

7.  Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.

Authors:  R G Gish; N W Y Leung; T L Wright; Huy Trinh; W Lang; H A Kessler; L Fang; L H Wang; J Delehanty; A Rigney; E Mondou; A Snow; F Rousseau
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

8.  Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection.

Authors:  Laurene H Wang; John Begley; Robert L St Claire; Jeanette Harris; Charles Wakeford; Franck S Rousseau
Journal:  AIDS Res Hum Retroviruses       Date:  2004-11       Impact factor: 2.205

9.  Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil).

Authors:  F S Rousseau; J O Kahn; M Thompson; D Mildvan; D Shepp; J P Sommadossi; J Delehanty; J N Simpson; L H Wang; J B Quinn; C Wakeford; C van der Horst
Journal:  J Antimicrob Chemother       Date:  2001-10       Impact factor: 5.790

10.  Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers.

Authors:  M Robert Blum; Gregory E Chittick; John A Begley; Jian Zong
Journal:  J Clin Pharmacol       Date:  2007-06       Impact factor: 3.126

View more
  19 in total

Review 1.  Clinical Pharmacology in HIV Therapy.

Authors:  Mohamed G Atta; Sophie De Seigneux; Gregory M Lucas
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-29       Impact factor: 8.237

Review 2.  Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.

Authors:  Dario Cattaneo; Cristina Gervasoni
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

3.  Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics.

Authors:  Elodie Valade; Jean-Marc Tréluyer; François Dabis; Elise Arrivé; Emmanuelle Pannier; Sihem Benaboud; Floris Fauchet; Naïm Bouazza; Frantz Foissac; Saïk Urien; Déborah Hirt
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

4.  Dysregulation of Endoplasmic Reticulum Stress and Autophagic Responses by the Antiretroviral Drug Efavirenz.

Authors:  Luc Bertrand; Michal Toborek
Journal:  Mol Pharmacol       Date:  2015-05-18       Impact factor: 4.436

5.  Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.

Authors:  Laura Dickinson; H Manisha Yapa; Akil Jackson; Graeme Moyle; Laura Else; Alieu Amara; Saye Khoo; David Back; Zeenat Karolia; Chris Higgs; Marta Boffito
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

6.  Emtricitabine seminal plasma and blood plasma population pharmacokinetics in HIV-infected men in the EVARIST ANRS-EP 49 study.

Authors:  Elodie Valade; Jean-Marc Tréluyer; Silvia M Illamola; Naïm Bouazza; Frantz Foissac; Maïlys De Sousa Mendes; Gabrielle Lui; Camille Chenevier-Gobeaux; Marie Suzan-Monti; Christine Rouzioux; Lambert Assoumou; Jean-Paul Viard; Déborah Hirt; Saïk Urien; Jade Ghosn
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

7.  HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy.

Authors:  Sangeetha Satheesan; Haitang Li; John C Burnett; Mayumi Takahashi; Shasha Li; Shiny Xiaqin Wu; Timothy W Synold; John J Rossi; Jiehua Zhou
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

8.  Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.

Authors:  Rajith K R Rajoli; David J Back; Steve Rannard; Caren L Freel Meyers; Charles Flexner; Andrew Owen; Marco Siccardi
Journal:  Clin Pharmacokinet       Date:  2015-06       Impact factor: 6.447

9.  Prediction of Maternal and Fetal Acyclovir, Emtricitabine, Lamivudine, and Metformin Concentrations during Pregnancy Using a Physiologically Based Pharmacokinetic Modeling Approach.

Authors:  Khaled Abduljalil; Amita Pansari; Jia Ning; Masoud Jamei
Journal:  Clin Pharmacokinet       Date:  2022-01-24       Impact factor: 6.447

10.  Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 Study.

Authors:  Selwyn J Hurwitz; Sijia Tao; Christina Gavegnano; Yong Jiang; Randall L Tressler; Athe Tsibris; Carlos Del Rio; Edgar T Overton; Michael M Lederman; Amy Kantor; Carlee Moser; James J Kohler; Jeffrey Lennox; Vincent C Marconi; Charles W Flexner; Raymond F Schinazi
Journal:  J Clin Pharmacol       Date:  2021-07-23       Impact factor: 2.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.